Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:tertiary carboxamide
go back to main search page
Accession:CHEBI:140326 term browser browse the term
Definition:A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
Synonyms:related_synonym: Formula=CNOR3;   SMILES=N(C(*)=O)(*)*;   tertiary carboxamides


show annotations for term's descendants           Sort by:
 
acalabrutinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crp C-reactive protein, pentraxin-related affects expression ISO acalabrutinib affects the expression of CRP protein CTD PMID:32503877 NCBI chr 1:172,698,056...172,699,966
Ensembl chr 1:172,698,055...172,833,031
JBrowse link
G Il6 interleukin 6 decreases expression ISO acalabrutinib results in decreased expression of IL6 protein CTD PMID:32503877 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
butachlor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor increases activity ISO butachlor results in increased activity of AR protein CTD PMID:20143881 NCBI chr  X:98,148,757...98,323,218
Ensembl chr  X:98,148,769...98,323,215
JBrowse link
G Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 increases metabolic processing ISO CYP2B6 protein results in increased metabolism of butachlor CTD PMID:11133395 NCBI chr 7:25,897,658...25,926,624
Ensembl chr 7:25,897,620...25,926,624
JBrowse link
G Dio1 deiodinase, iodothyronine, type I decreases activity ISO butachlor results in decreased activity of DIO1 protein CTD PMID:29228274 NCBI chr 4:107,291,465...107,307,168
Ensembl chr 4:107,291,465...107,307,169
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity ISO butachlor results in increased activity of NR1H4 protein CTD PMID:20143881 NCBI chr10:89,454,234...89,533,645
Ensembl chr10:89,454,234...89,533,585
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases activity ISO butachlor results in increased activity of NR3C1 protein CTD PMID:20143881 NCBI chr18:39,410,545...39,519,421
Ensembl chr18:39,410,545...39,519,421
JBrowse link
G Thrb thyroid hormone receptor beta affects binding ISO butachlor binds to THRB protein CTD PMID:28973306 NCBI chr14:17,659,225...18,040,097
Ensembl chr14:17,660,261...18,038,090
JBrowse link
camostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cckar cholecystokinin A receptor increases expression ISO camostat results in increased expression of CCKAR mRNA CTD PMID:10458643 NCBI chr 5:53,698,485...53,707,704
Ensembl chr 5:53,697,776...53,707,705
JBrowse link
G Ccl2 chemokine (C-C motif) ligand 2 multiple interactions ISO camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA] CTD PMID:27773435 NCBI chr11:82,035,577...82,037,452
Ensembl chr11:82,035,571...82,037,453
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO camostat inhibits the reaction [Adenine results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA] CTD PMID:25766432 PMID:27773435 NCBI chr10:24,595,442...24,598,683
Ensembl chr10:24,595,442...24,598,683
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
EXP PD 0325901 inhibits the reaction [camostat results in increased expression of CCND1 protein] CTD PMID:25104499 NCBI chr 7:144,929,931...144,939,831
Ensembl chr 7:144,929,931...144,939,925
JBrowse link
G Ccnd3 cyclin D3 increases expression
multiple interactions
EXP camostat results in increased expression of CCND3 protein
PD 0325901 inhibits the reaction [camostat results in increased expression of CCND3 protein]
CTD PMID:25104499 NCBI chr17:47,505,051...47,599,689
Ensembl chr17:47,505,051...47,599,691
JBrowse link
G Ccne1 cyclin E1 increases expression
multiple interactions
EXP camostat results in increased expression of CCNE1 protein
PD 0325901 inhibits the reaction [camostat results in increased expression of CCNE1 protein]
CTD PMID:25104499 NCBI chr 7:38,097,984...38,107,490
Ensembl chr 7:38,097,984...38,107,534
JBrowse link
G Col1a1 collagen, type I, alpha 1 multiple interactions ISO camostat inhibits the reaction [Adenine results in increased expression of COL1A1 mRNA] CTD PMID:25766432 NCBI chr11:94,936,224...94,953,042
Ensembl chr11:94,936,224...94,953,042
JBrowse link
G Col3a1 collagen, type III, alpha 1 multiple interactions ISO camostat inhibits the reaction [Adenine results in increased expression of COL3A1 mRNA] CTD PMID:25766432 NCBI chr 1:45,311,538...45,349,706
Ensembl chr 1:45,311,538...45,349,706
JBrowse link
G Cybb cytochrome b-245, beta polypeptide multiple interactions ISO camostat inhibits the reaction [Adenine results in increased expression of NOX2 mRNA] CTD PMID:25766432 NCBI chr  X:9,435,252...9,487,766
Ensembl chr  X:9,435,252...9,487,771
JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression
EXP PD 0325901 inhibits the reaction [camostat results in increased expression of EGR1 mRNA] CTD PMID:25104499 NCBI chr18:34,861,207...34,864,956
Ensembl chr18:34,859,823...34,864,984
JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions EXP camostat results in increased expression of and results in increased secretion of FGF21 protein CTD PMID:30920846 NCBI chr 7:45,613,890...45,615,490
Ensembl chr 7:45,613,886...45,615,490
JBrowse link
G Fos FBJ osteosarcoma oncogene increases expression
multiple interactions
EXP camostat results in increased expression of FOS mRNA
PD 0325901 inhibits the reaction [camostat results in increased expression of FOS mRNA]
CTD PMID:25104499 NCBI chr12:85,473,890...85,477,274
Ensembl chr12:85,473,890...85,477,273
JBrowse link
G Ier3 immediate early response 3 increases expression EXP camostat results in increased expression of IER3 mRNA CTD PMID:25104499 NCBI chr17:35,821,713...35,822,911
Ensembl chr17:35,821,684...35,822,923
JBrowse link
G Jun jun proto-oncogene increases expression
increases phosphorylation
EXP camostat results in increased expression of JUN mRNA
camostat results in increased phosphorylation of JUN protein
CTD PMID:25104499 NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
JBrowse link
G Junb jun B proto-oncogene increases expression EXP camostat results in increased expression of JUNB mRNA CTD PMID:25104499 NCBI chr 8:84,976,909...84,978,748
Ensembl chr 8:84,974,484...84,978,718
Ensembl chr 8:84,974,484...84,978,718
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 increases phosphorylation
multiple interactions
EXP camostat results in increased phosphorylation of MAPK1 protein
PD 0325901 inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]
CTD PMID:25104499 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 increases phosphorylation
multiple interactions
EXP camostat results in increased phosphorylation of MAPK3 protein
PD 0325901 inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]
CTD PMID:25104499 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Mki67 antigen identified by monoclonal antibody Ki 67 increases expression
multiple interactions
EXP camostat results in increased expression of MKI67 protein
PD 0325901 inhibits the reaction [camostat results in increased expression of MKI67 protein]
CTD PMID:25104499 NCBI chr 7:135,689,784...135,716,450
Ensembl chr 7:135,689,784...135,716,361
JBrowse link
G Nos3 nitric oxide synthase 3, endothelial cell increases expression ISO camostat results in increased expression of NOS3 mRNA CTD PMID:10458643 NCBI chr 5:24,364,816...24,384,474
Ensembl chr 5:24,364,810...24,384,474
JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions ISO camostat inhibits the reaction [Adenine results in increased expression of NOX1 mRNA] CTD PMID:25766432 NCBI chr  X:134,086,421...134,137,711
Ensembl chr  X:134,086,421...134,221,956
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
increases expression
EXP PD 0325901 inhibits the reaction [camostat results in increased expression of PCNA protein] CTD PMID:25104499 NCBI chr 2:132,249,286...132,253,180
Ensembl chr 2:132,249,162...132,253,314
JBrowse link
G Plg plasminogen decreases activity
multiple interactions
ISO camostat results in decreased activity of PLG protein modified form
camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]
CTD PMID:27773435 NCBI chr17:12,378,609...12,419,384
Ensembl chr17:12,378,608...12,419,385
JBrowse link
G Rps6 ribosomal protein S6 increases phosphorylation EXP camostat results in increased phosphorylation of RPS6 protein CTD PMID:25104499 NCBI chr 4:86,854,099...86,857,367
Ensembl chr 4:86,854,660...86,857,412
JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 multiple interactions ISO camostat inhibits the reaction [Adenine results in increased expression of SERPINE1 mRNA] CTD PMID:25766432 NCBI chr 5:137,061,504...137,072,272
Ensembl chr 5:137,061,504...137,072,268
JBrowse link
G Smad2 SMAD family member 2 multiple interactions EXP camostat inhibits the reaction [Bleomycin results in increased phosphorylation of SMAD2 protein] CTD PMID:26599507 NCBI chr18:76,241,090...76,311,748
Ensembl chr18:76,241,580...76,310,963
JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases phosphorylation EXP camostat results in increased phosphorylation of STAT3 protein CTD PMID:25104499 NCBI chr11:100,886,806...100,939,594
Ensembl chr11:100,885,098...100,939,540
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP
ISO
camostat inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]
camostat inhibits the reaction [Adenine results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]
CTD PMID:25766432 PMID:26599507 PMID:27773435 NCBI chr 7:25,687,002...25,705,077
Ensembl chr 7:25,687,002...25,705,077
JBrowse link
G Tmprss2 transmembrane protease, serine 2 decreases activity ISO camostat results in decreased activity of TMPRSS2 protein CTD PMID:24027332 NCBI chr16:97,564,682...97,659,541
Ensembl chr16:97,564,682...97,611,195
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP
ISO
camostat inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]
CTD PMID:20023007 PMID:27773435 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link
carfentanil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2c29 cytochrome P450, family 2, subfamily c, polypeptide 29 increases metabolic processing ISO CYP2C8 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr19:39,287,044...39,330,713
Ensembl chr19:39,269,405...39,330,713
JBrowse link
G Cyp2c65 cytochrome P450, family 2, subfamily c, polypeptide 65 increases metabolic processing ISO CYP2C9 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr19:39,061,006...39,093,948
Ensembl chr19:39,061,015...39,093,944
JBrowse link
G Cyp2c66 cytochrome P450, family 2, subfamily c, polypeptide 66 increases metabolic processing ISO CYP2C9 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr19:39,113,898...39,186,756
Ensembl chr19:39,113,898...39,187,072
JBrowse link
G Cyp3a11 cytochrome P450, family 3, subfamily a, polypeptide 11 increases metabolic processing ISO CYP3A5 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr 5:145,854,607...145,879,854
Ensembl chr 5:145,854,426...145,879,964
JBrowse link
G Oprm1 opioid receptor, mu 1 multiple interactions ISO Capsaicin inhibits the reaction [carfentanil binds to OPRM1 protein]; Cocaine affects the reaction [carfentanil binds to OPRM1 protein] CTD PMID:12406535 PMID:15953495 NCBI chr10:6,758,593...7,038,209
Ensembl chr10:6,758,506...7,038,198
JBrowse link
crotamiton term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO crotamiton results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr 1:171,213,934...171,218,845
Ensembl chr 1:171,213,970...171,220,701
JBrowse link
dimethomorph term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Anxa10 annexin A10 increases expression ISO dimethomorph results in increased expression of ANXA10 mRNA CTD PMID:32194361 NCBI chr 8:62,057,042...62,123,193
Ensembl chr 8:62,057,042...62,123,150
JBrowse link
G Ar androgen receptor multiple interactions ISO dimethomorph inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; dimethomorph inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] CTD PMID:21310686 PMID:33049310 NCBI chr  X:98,148,757...98,323,218
Ensembl chr  X:98,148,769...98,323,215
JBrowse link
G Arg1 arginase, liver decreases expression ISO dimethomorph results in decreased expression of ARG1 mRNA CTD PMID:32194361 NCBI chr10:24,915,207...24,927,470
Ensembl chr10:24,915,221...24,927,484
JBrowse link
G Cyp2c38 cytochrome P450, family 2, subfamily c, polypeptide 38 decreases expression ISO dimethomorph results in decreased expression of CYP2C19 protein CTD PMID:32194361 NCBI chr19:39,389,556...39,463,103
Ensembl chr19:39,389,556...39,463,075
JBrowse link
G Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 decreases expression ISO dimethomorph results in decreased expression of CYP7A1 mRNA; dimethomorph results in decreased expression of CYP7A1 protein CTD PMID:32194361 NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
JBrowse link
G Esr1 estrogen receptor 1 (alpha) multiple interactions ISO dimethomorph binds to and results in increased activity of ESR1 protein CTD PMID:33049310 NCBI chr10:4,611,989...5,005,633
Ensembl chr10:4,611,593...5,005,614
JBrowse link
G G6pc glucose-6-phosphatase, catalytic decreases expression ISO dimethomorph results in decreased expression of G6PC1 mRNA CTD PMID:32194361 NCBI chr11:101,367,716...101,377,903
Ensembl chr11:101,367,561...101,377,903
JBrowse link
G Gm40318 predicted gene, 40318 increases expression ISO dimethomorph results in increased expression of S100P mRNA; dimethomorph results in increased expression of S100P protein CTD PMID:32194361 NCBI chr 5:36,762,504...36,767,419
Ensembl chr 5:36,762,617...36,766,695
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO
EXP
dimethomorph binds to and results in increased activity of NR1I2 protein CTD PMID:33049310 NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
JBrowse link
G Pde4a phosphodiesterase 4A, cAMP specific decreases activity ISO dimethomorph results in decreased activity of PDE4A protein CTD PMID:21251949 NCBI chr 9:21,165,700...21,213,248
Ensembl chr 9:21,165,714...21,213,248
JBrowse link
G Pparg peroxisome proliferator activated receptor gamma multiple interactions EXP
ISO
dimethomorph binds to and results in increased activity of PPARG protein CTD PMID:33049310 NCBI chr 6:115,360,879...115,490,404
Ensembl chr 6:115,360,951...115,490,399
JBrowse link
erastin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atg5 autophagy related 5 increases expression ISO erastin results in increased expression of ATG5 protein CTD PMID:32937103 NCBI chr10:44,268,322...44,364,299
Ensembl chr10:44,268,358...44,364,291
JBrowse link
G Chac1 ChaC, cation transport regulator 1 multiple interactions
increases expression
EXP GW 506033X inhibits the reaction [erastin results in increased expression of CHAC1 mRNA] CTD PMID:30817950 NCBI chr 2:119,351,242...119,354,326
Ensembl chr 2:119,351,229...119,354,381
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO erastin affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol] CTD PMID:33017621 NCBI chr 7:140,763,819...140,774,990
Ensembl chr 7:140,763,739...140,774,987
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions
EXP erastin results in increased expression of DDIT3 mRNA
GW 506033X inhibits the reaction [erastin results in increased expression of DDIT3 mRNA]
CTD PMID:30817950 NCBI chr10:127,290,793...127,296,291
Ensembl chr10:127,290,774...127,296,288
Ensembl chr10:127,290,774...127,296,288
JBrowse link
G Ern1 endoplasmic reticulum (ER) to nucleus signalling 1 multiple interactions
increases phosphorylation
EXP GW 506033X inhibits the reaction [erastin results in increased phosphorylation of ERN1 protein] CTD PMID:30817950 NCBI chr11:106,397,620...106,487,796
Ensembl chr11:106,394,650...106,487,852
JBrowse link
G Fancd2 Fanconi anemia, complementation group D2 decreases expression ISO erastin results in decreased expression of FANCD2 protein CTD PMID:32937103 NCBI chr 6:113,531,640...113,597,020
Ensembl chr 6:113,531,682...113,597,017
JBrowse link
G Fh1 fumarate hydratase 1 decreases response to substance ISO FH protein results in decreased susceptibility to erastin CTD PMID:29917289 NCBI chr 1:175,601,378...175,625,635
Ensembl chr 1:175,600,374...175,625,635
JBrowse link
G Fth1 ferritin heavy polypeptide 1 multiple interactions
increases expression
ISO 3-methyladenine promotes the reaction [erastin results in increased expression of FTH1 protein]; Chloroquine promotes the reaction [erastin results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein] CTD PMID:32937103 NCBI chr19:9,980,600...9,985,111
Ensembl chr19:9,980,598...9,985,098
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
ISO NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein] CTD PMID:32937103 NCBI chr 9:77,754,535...77,794,489
Ensembl chr 9:77,754,535...77,794,485
JBrowse link
G Gclm glutamate-cysteine ligase, modifier subunit multiple interactions
increases expression
ISO NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein] CTD PMID:32937103 NCBI chr 3:122,245,487...122,267,215
Ensembl chr 3:122,245,557...122,270,732
JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression
multiple interactions
ISO erastin results in decreased expression of GPX4 protein
SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein]
CTD PMID:31323261 PMID:32937103 NCBI chr10:80,047,166...80,056,439
Ensembl chr10:80,047,166...80,056,439
JBrowse link
G Hmox1 heme oxygenase 1 increases expression EXP erastin results in increased expression of HMOX1 protein CTD PMID:30817950 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Hras Harvey rat sarcoma virus oncogene increases response to substance ISO HRAS protein modified form results in increased susceptibility to erastin CTD PMID:17568748 NCBI chr 7:141,189,934...141,194,019
Ensembl chr 7:141,189,105...141,194,005
JBrowse link
G Hspb1 heat shock protein 1 decreases phosphorylation ISO erastin results in decreased phosphorylation of HSPB1 protein CTD PMID:32937103 NCBI chr 5:135,887,919...135,889,563
Ensembl chr 5:135,887,919...135,889,563
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
multiple interactions
ISO erastin results in increased expression of MAP1LC3B protein modified form
3-methyladenine inhibits the reaction [erastin results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [erastin results in increased expression of MAP1LC3B protein modified form]
CTD PMID:32937103 NCBI chr 8:121,590,438...121,598,760
Ensembl chr 8:121,590,361...121,598,760
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation
EXP GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK1 protein] CTD PMID:30817950 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK3 protein] CTD PMID:30817950 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions
EXP erastin results in increased phosphorylation of MAPK8 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK8 protein]
CTD PMID:30817950 NCBI chr14:33,377,898...33,447,353
Ensembl chr14:33,377,898...33,447,158
JBrowse link
G Ncoa4 nuclear receptor coactivator 4 decreases expression
multiple interactions
ISO erastin results in decreased expression of NCOA4 protein
3-methyladenine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]; Chloroquine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]
CTD PMID:32937103 NCBI chr14:32,159,879...32,179,855
Ensembl chr14:32,159,865...32,179,855
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions
increases expression
ISO
EXP
NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of NFE2L2 protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]
CTD PMID:31323261 PMID:32937103 NCBI chr 2:75,675,513...75,704,663
Ensembl chr 2:75,675,513...75,704,641
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO
EXP
erastin results in increased expression of PTGS2 mRNA
erastin analog results in increased expression of PTGS2 mRNA
erastin analog results in increased expression of PTGS2 mRNA; erastin results in increased expression of PTGS2 mRNA
Vitamin E inhibits the reaction [erastin analog results in increased expression of PTGS2 mRNA]
CTD PMID:24439385 PMID:32937103 NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
JBrowse link
G Sesn1 sestrin 1 multiple interactions ISO SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein] CTD PMID:31323261 NCBI chr10:41,810,574...41,908,436
Ensembl chr10:41,809,935...41,908,424
JBrowse link
G Sesn2 sestrin 2 increases expression
multiple interactions
EXP
ISO
erastin results in increased expression of SESN2 mRNA; erastin results in increased expression of SESN2 protein
Acetylcysteine inhibits the reaction [erastin results in increased expression of SESN2 protein]; Butylated Hydroxyanisole inhibits the reaction [erastin results in increased expression of SESN2 protein]; Dactinomycin inhibits the reaction [erastin results in increased expression of SESN2 mRNA]; Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein]; diphenyleneiodonium inhibits the reaction [erastin results in increased expression of SESN2 protein]; ferrostatin-1 inhibits the reaction [erastin results in increased expression of SESN2 protein]; NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
CTD PMID:31323261 NCBI chr 4:132,492,804...132,510,456
Ensembl chr 4:132,492,032...132,510,501
JBrowse link
G Slc11a2 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 increases expression ISO erastin results in increased expression of SLC11A2 protein CTD PMID:32937103 NCBI chr15:100,387,898...100,424,209
Ensembl chr15:100,387,898...100,425,072
JBrowse link
G Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 decreases expression
increases expression
ISO erastin results in decreased expression of SLC40A1 protein
erastin results in increased expression of SLC40A1 protein
CTD PMID:31323261 PMID:32937103 NCBI chr 1:45,908,070...45,926,532
Ensembl chr 1:45,908,068...45,926,523
JBrowse link
G Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 increases expression
multiple interactions
ISO erastin results in increased expression of SLC7A11 mRNA
NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]
CTD PMID:32937103 NCBI chr 3:50,364,936...50,499,087
Ensembl chr 3:49,892,526...50,443,614
JBrowse link
G Tfrc transferrin receptor increases expression ISO erastin results in increased expression of TFRC protein CTD PMID:31323261 PMID:32937103 NCBI chr16:32,608,896...32,632,794
Ensembl chr16:32,608,920...32,632,794
JBrowse link
G Trf transferrin increases expression ISO erastin results in increased expression of TF protein CTD PMID:32937103 NCBI chr 9:103,208,876...103,230,286
Ensembl chr 9:103,204,001...103,230,444
JBrowse link
G Vdac2 voltage-dependent anion channel 2 affects binding
increases degradation
decreases expression
ISO erastin analog binds to VDAC2 protein
erastin results in increased degradation of VDAC2 protein
erastin results in decreased expression of VDAC2 protein
CTD PMID:17568748 PMID:32937103 NCBI chr14:21,831,561...21,845,879
Ensembl chr14:21,825,238...21,845,879
JBrowse link
G Vdac3 voltage-dependent anion channel 3 decreases expression
increases degradation
affects response to substance
ISO erastin results in decreased expression of VDAC3 protein
erastin results in increased degradation of VDAC3 protein
VDAC3 protein affects the susceptibility to erastin
CTD PMID:17568748 PMID:32937103 NCBI chr 8:22,577,075...22,593,813
Ensembl chr 8:22,577,075...22,593,813
JBrowse link
GSK2656157 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atf4 activating transcription factor 4 multiple interactions EXP GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein] CTD PMID:30602124 PMID:32578922 NCBI chr15:80,255,184...80,257,545
Ensembl chr15:80,255,184...80,257,541
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2, subunit 1 alpha multiple interactions EXP
ISO
GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]
CTD PMID:30602124 PMID:32357311 NCBI chr12:78,862,072...78,887,010
Ensembl chr12:78,861,819...78,887,010
JBrowse link
G Ostn osteocrin multiple interactions EXP GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA] CTD PMID:30602124 NCBI chr16:27,307,641...27,351,209
Ensembl chr16:27,307,489...27,351,212
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions ISO GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] CTD PMID:32357311 NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254
JBrowse link
ibrutinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin affects binding ISO ibrutinib binds to ALB protein CTD PMID:26675335 NCBI chr 5:90,460,870...90,476,602
Ensembl chr 5:90,460,897...90,476,602
JBrowse link
G Bcl2l1 BCL2-like 1 decreases expression ISO ibrutinib results in decreased expression of BCL2L1 mRNA CTD PMID:26254443 NCBI chr 2:152,758,732...152,833,803
Ensembl chr 2:152,780,668...152,831,728
JBrowse link
G Bcl2l11 BCL2-like 11 (apoptosis facilitator) multiple interactions ISO ibrutinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] CTD PMID:26254443 NCBI chr 2:128,126,038...128,162,547
Ensembl chr 2:128,126,038...128,162,547
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO ibrutinib results in decreased expression of BIRC3 mRNA CTD PMID:26254443 NCBI chr 9:7,847,468...7,873,205
Ensembl chr 9:7,848,699...7,873,186
JBrowse link
G Bmi1 Bmi1 polycomb ring finger oncogene decreases expression ISO ibrutinib results in decreased expression of BMI1 mRNA CTD PMID:26254443 NCBI chr 2:18,677,018...18,686,629
Ensembl chr 2:18,677,018...18,686,629
JBrowse link
G Btk Bruton agammaglobulinemia tyrosine kinase decreases response to substance
decreases activity
decreases phosphorylation
multiple interactions
affects binding
ISO BTK gene mutant form results in decreased susceptibility to ibrutinib; BTK protein mutant form results in decreased susceptibility to ibrutinib
ibrutinib results in decreased activity of BTK protein
ibrutinib results in decreased phosphorylation of BTK protein
(+)-JQ1 compound promotes the reaction [ibrutinib results in decreased phosphorylation of and results in decreased expression of BTK protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of and results in decreased expression of BTK protein]; ibrutinib results in decreased phosphorylation of and results in decreased expression of BTK protein
ibrutinib binds to BTK protein
CTD PMID:23296407 PMID:23425038 PMID:25189416 PMID:26174628 PMID:26254443 PMID:26675335 NCBI chr  X:134,542,334...134,583,628
Ensembl chr  X:134,542,336...134,583,570
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression ISO ibrutinib results in decreased expression of CFLAR mRNA CTD PMID:26254443 NCBI chr 1:58,711,311...58,758,884
Ensembl chr 1:58,711,508...58,758,884
JBrowse link
G Crebbp CREB binding protein decreases response to substance ISO CREBBP protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr16:4,081,334...4,213,957
Ensembl chr16:4,081,328...4,213,997
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble increases secretion ISO ibrutinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr15:76,696,726...76,699,675
Ensembl chr15:76,695,716...76,699,686
JBrowse link
G Hbb-b1 hemoglobin, beta adult major chain affects binding ISO ibrutinib binds to HBB protein CTD PMID:26675335
G Ikbkb inhibitor of kappaB kinase beta multiple interactions
decreases activity
ISO (+)-JQ1 compound promotes the reaction [ibrutinib results in decreased activity of IKBKB protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased activity of IKBKB protein] CTD PMID:25049379 NCBI chr 8:22,659,205...22,706,589
Ensembl chr 8:22,659,212...22,706,589
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
ISO ibrutinib promotes the reaction [CPI203 results in decreased expression of IL10 mRNA]
ibrutinib results in decreased expression of IL10 mRNA
CTD PMID:25049379 PMID:26254443 NCBI chr 1:131,019,845...131,024,970
Ensembl chr 1:131,019,845...131,024,974
JBrowse link
G Il6 interleukin 6 multiple interactions ISO ibrutinib promotes the reaction [CPI203 results in decreased expression of IL6 mRNA] CTD PMID:25049379 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 decreases response to substance ISO MAP3K14 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr11:103,219,764...103,267,401
Ensembl chr11:103,219,762...103,267,472
JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha decreases expression ISO ibrutinib results in decreased expression of NFKBIA mRNA CTD PMID:26254443 NCBI chr12:55,489,409...55,492,647
Ensembl chr12:55,489,410...55,492,647
JBrowse link
G Pim1 proviral integration site 1 decreases response to substance ISO PIM1 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr17:29,490,785...29,496,111
Ensembl chr17:29,490,753...29,496,112
JBrowse link
G Plcg2 phospholipase C, gamma 2 multiple interactions
decreases response to substance
decreases phosphorylation
ISO (+)-JQ1 compound promotes the reaction [ibrutinib results in decreased phosphorylation of PLCG2 protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of PLCG2 protein]
PLCG2 protein mutant form results in decreased susceptibility to ibrutinib
CTD PMID:26254443 PMID:27542411 NCBI chr 8:117,498,275...117,635,142
Ensembl chr 8:117,498,291...117,635,142
JBrowse link
G Prdm1 PR domain containing 1, with ZNF domain decreases expression ISO ibrutinib results in decreased expression of PRDM1 mRNA CTD PMID:26254443 NCBI chr10:44,437,174...44,528,558
Ensembl chr10:44,437,177...44,528,501
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) affects localization ISO ibrutinib affects the localization of RELA protein CTD PMID:26254443 NCBI chr19:5,637,442...5,648,134
Ensembl chr19:5,637,483...5,648,130
JBrowse link
G Tnf tumor necrosis factor decreases expression ISO ibrutinib results in decreased expression of TNF mRNA CTD PMID:26254443 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link
G Tnfaip3 tumor necrosis factor, alpha-induced protein 3 decreases expression ISO ibrutinib results in decreased expression of TNFAIP3 mRNA CTD PMID:26254443 NCBI chr10:19,000,910...19,015,410
Ensembl chr10:19,000,910...19,015,657
JBrowse link
G Traf2 TNF receptor-associated factor 2 decreases response to substance ISO TRAF2 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr 2:25,517,982...25,546,940
Ensembl chr 2:25,517,982...25,546,940
JBrowse link
G Traf3 TNF receptor-associated factor 3 decreases response to substance ISO TRAF3 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr12:111,166,321...111,267,155
Ensembl chr12:111,166,370...111,267,153
JBrowse link
mefenacet term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO Dihydrotestosterone inhibits the reaction [mefenacet results in increased activity of AR protein] CTD PMID:15064155 NCBI chr  X:98,148,757...98,323,218
Ensembl chr  X:98,148,769...98,323,215
JBrowse link
G Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 multiple interactions ISO CYP2B6 protein results in increased metabolism of and results in decreased susceptibility to mefenacet CTD PMID:15853388 NCBI chr 7:25,897,658...25,926,624
Ensembl chr 7:25,897,620...25,926,624
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO
EXP
mefenacet binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
JBrowse link
PHA-665752 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 thymoma viral proto-oncogene 1 multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of AKT1 protein] CTD PMID:22040890 PMID:25002221 NCBI chr12:112,653,821...112,674,884
Ensembl chr12:112,653,821...112,674,884
JBrowse link
G Bcl2l1 BCL2-like 1 decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of BCL2L1 protein CTD PMID:20661229 NCBI chr 2:152,758,732...152,833,803
Ensembl chr 2:152,780,668...152,831,728
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein
Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein]
CTD PMID:20661229 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Cat catalase multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in decreased expression of CAT protein] CTD PMID:22040890 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Egfr epidermal growth factor receptor decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]
CTD PMID:21266357 NCBI chr11:16,752,203...16,913,907
Ensembl chr11:16,752,203...16,918,158
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] CTD PMID:20661229 PMID:21812414 NCBI chr 5:16,553,495...16,619,439
Ensembl chr 5:16,553,495...16,620,152
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Met met proto-oncogene decreases activity
increases mutagenesis
decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased activity of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of and results in decreased activity of MET protein; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to crizotinib; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]
CTD PMID:20661229 PMID:21106725 PMID:21266357 PMID:21812414 PMID:25002221 NCBI chr 6:17,463,349...17,573,980
Ensembl chr 6:17,463,800...17,573,980
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
CTD PMID:21266357 NCBI chr 4:86,854,099...86,857,367
Ensembl chr 4:86,854,660...86,857,412
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
increases response to substance
increases expression
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein
CTD PMID:21266357 NCBI chr 6:86,195,038...86,275,744
Ensembl chr 6:86,195,223...86,275,719
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of XIAP protein CTD PMID:20661229 NCBI chr  X:42,059,613...42,109,664
Ensembl chr  X:42,059,679...42,109,656
JBrowse link
piperine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A multiple interactions
increases expression
ISO Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]
piperine results in increased expression of ABCB1 mRNA; piperine results in increased expression of ABCB1 protein
CTD PMID:23707768 NCBI chr 5:8,567,091...8,748,575
Ensembl chr 5:8,660,077...8,748,575
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO piperine inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] CTD PMID:25087745 NCBI chr16:23,146,536...23,157,968
Ensembl chr16:23,146,536...23,158,028
JBrowse link
G Akt1 thymoma viral proto-oncogene 1 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein] CTD PMID:25655587 NCBI chr12:112,653,821...112,674,884
Ensembl chr12:112,653,821...112,674,884
JBrowse link
G Alb albumin multiple interactions ISO piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]] CTD PMID:17429802 NCBI chr 5:90,460,870...90,476,602
Ensembl chr 5:90,460,897...90,476,602
JBrowse link
G Atf2 activating transcription factor 2 decreases localization ISO piperine results in decreased localization of ATF2 protein CTD PMID:15531295 NCBI chr 2:73,816,509...73,892,677
Ensembl chr 2:73,816,509...73,892,639
JBrowse link
G Bax BCL2-associated X protein increases expression
multiple interactions
ISO piperine results in increased expression of BAX protein
piperine inhibits the reaction [Curcumin results in decreased expression of BAX protein]
CTD PMID:28341137 PMID:30935902 NCBI chr 7:45,461,695...45,466,903
Ensembl chr 7:45,461,697...45,466,898
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 decreases expression
multiple interactions
ISO piperine results in decreased expression of BCL2 protein
[piperine co-treated with Curcumin] results in decreased expression of BCL2 protein
CTD PMID:28341137 PMID:30935902 NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
EXP
ISO
piperine inhibits the reaction [Cadmium results in increased activity of CASP3 protein]
piperine inhibits the reaction [Curcumin results in decreased expression of CASP3 protein]
piperine results in increased cleavage of CASP3 protein
CTD PMID:16780805 PMID:28341137 PMID:30935902 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Casp9 caspase 9 increases cleavage ISO piperine results in increased cleavage of CASP9 protein CTD PMID:28341137 NCBI chr 4:141,793,612...141,815,978
Ensembl chr 4:141,793,612...141,815,976
JBrowse link
G Cat catalase multiple interactions
decreases expression
ISO piperine inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]
piperine results in decreased expression of CAT protein
CTD PMID:25087745 PMID:28341137 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Ccnb1 cyclin B1 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased expression of CCNB1 protein] CTD PMID:25655587 NCBI chr13:100,778,739...100,786,486
Ensembl chr13:100,778,650...100,786,570
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO piperine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein] CTD PMID:30935902 NCBI chr 7:144,929,931...144,939,831
Ensembl chr 7:144,929,931...144,939,925
JBrowse link
G Ccnd2 cyclin D2 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased expression of CCND2 protein] CTD PMID:25655587 NCBI chr 6:127,125,162...127,152,188
Ensembl chr 6:127,125,162...127,152,193
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased expression of CDC25C protein] CTD PMID:25655587 NCBI chr18:34,732,993...34,751,564
Ensembl chr18:34,732,993...34,751,533
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased expression of CDK1 protein] CTD PMID:25655587 NCBI chr10:69,335,146...69,352,912
Ensembl chr10:69,335,146...69,352,938
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased expression of CDK4 protein] CTD PMID:25655587 NCBI chr10:127,063,535...127,067,288
Ensembl chr10:127,063,534...127,067,920
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased expression of CDK6 protein] CTD PMID:25655587 NCBI chr 5:3,341,004...3,531,008
Ensembl chr 5:3,341,485...3,531,008
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of CDKN1A protein CTD PMID:30935902 NCBI chr17:29,090,979...29,100,722
Ensembl chr17:29,090,976...29,100,727
JBrowse link
G Creb1 cAMP responsive element binding protein 1 decreases localization ISO piperine results in decreased localization of CREB1 protein CTD PMID:15531295 NCBI chr 1:64,532,794...64,604,548
Ensembl chr 1:64,532,645...64,604,548
JBrowse link
G Csf2 colony stimulating factor 2 (granulocyte-macrophage) decreases secretion
decreases expression
ISO piperine results in decreased secretion of CSF2 protein
piperine results in decreased expression of CSF2 mRNA
CTD PMID:15531295 NCBI chr11:54,247,270...54,249,899
Ensembl chr11:54,247,271...54,249,667
JBrowse link
G Ctnnb1 catenin (cadherin associated protein), beta 1 multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of CTNNB1 protein CTD PMID:30935902 NCBI chr 9:120,933,400...120,960,507
Ensembl chr 9:120,929,216...120,960,507
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO piperine affects the localization of CYCS protein CTD PMID:28341137 NCBI chr 6:50,562,563...50,566,569
Ensembl chr 6:50,562,563...50,566,538
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO piperine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:17012224 NCBI chr 9:57,687,928...57,703,824
Ensembl chr 9:57,687,928...57,703,824
JBrowse link
G Fgfr1 fibroblast growth factor receptor 1 affects binding ISO piperine binds to FGFR1 protein CTD PMID:28341137 NCBI chr 8:25,518,759...25,575,718
Ensembl chr 8:25,513,654...25,575,718
JBrowse link
G Fos FBJ osteosarcoma oncogene multiple interactions
decreases localization
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of FOS protein]
piperine results in decreased localization of FOS protein
CTD PMID:15531295 PMID:21354279 NCBI chr12:85,473,890...85,477,274
Ensembl chr12:85,473,890...85,477,273
JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions ISO piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]] CTD PMID:17429802 NCBI chr15:76,696,726...76,699,675
Ensembl chr15:76,695,716...76,699,686
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase multiple interactions ISO piperine inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein] CTD PMID:25087745 NCBI chr13:96,648,962...96,670,936
Ensembl chr13:96,648,967...96,670,936
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP
ISO
[Curcumin co-treated with piperine] results in increased expression of HMOX1 mRNA; [Curcumin co-treated with piperine] results in increased expression of HMOX1 protein; Acetylcysteine inhibits the reaction [[Curcumin co-treated with piperine] results in increased expression of HMOX1 protein]
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in increased expression of HMOX1 protein]
CTD PMID:12806184 PMID:23942037 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Ifng interferon gamma multiple interactions EXP [Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]; tin protoporphyrin IX inhibits the reaction [[Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]] CTD PMID:23942037 NCBI chr10:118,441,046...118,445,894
Ensembl chr10:118,441,046...118,445,892
JBrowse link
G Igf1r insulin-like growth factor I receptor affects binding ISO piperine binds to IGF1R protein CTD PMID:28341137 NCBI chr 7:67,952,257...68,233,668
Ensembl chr 7:67,952,827...68,233,668
JBrowse link
G Il1b interleukin 1 beta decreases expression
decreases secretion
ISO piperine results in decreased expression of IL1B mRNA
piperine results in decreased secretion of IL1B protein
CTD PMID:15531295 NCBI chr 2:129,364,569...129,371,164
Ensembl chr 2:129,364,570...129,371,139
JBrowse link
G Il2 interleukin 2 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased expression of CCNB1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDC25C protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK4 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK6 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:25655587 NCBI chr 3:37,120,713...37,125,954
Ensembl chr 3:37,120,523...37,125,959
JBrowse link
G Il6 interleukin 6 decreases secretion
decreases expression
ISO piperine results in decreased secretion of IL6 protein
piperine results in decreased expression of IL6 mRNA
CTD PMID:15531295 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
G Jun jun proto-oncogene multiple interactions ISO
EXP
piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein] CTD PMID:21354279 PMID:22542552 NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions ISO piperine inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein] CTD PMID:25087745 NCBI chr 8:105,939,551...105,943,402
Ensembl chr 8:105,939,551...105,943,382
JBrowse link
G Lep leptin multiple interactions ISO piperine inhibits the reaction [Dietary Fats results in increased expression of LEP protein] CTD PMID:25087745 NCBI chr 6:29,060,221...29,073,876
Ensembl chr 6:29,060,220...29,073,877
JBrowse link
G Lpl lipoprotein lipase multiple interactions ISO piperine inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] CTD PMID:25087745 NCBI chr 8:68,880,555...68,906,932
Ensembl chr 8:68,880,491...68,907,448
JBrowse link
G Maoa monoamine oxidase A multiple interactions
decreases activity
EXP
ISO
[resveratrol co-treated with piperine] results in decreased activity of MAOA protein
piperine results in decreased activity of MAOA protein
CTD PMID:15120460 PMID:23943324 NCBI chr  X:16,619,698...16,687,812
Ensembl chr  X:16,619,698...16,687,818
JBrowse link
G Maob monoamine oxidase B decreases activity ISO piperine results in decreased activity of MAOB protein CTD PMID:15120460 NCBI chr  X:16,709,281...16,817,366
Ensembl chr  X:16,709,282...16,817,366
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions ISO
EXP
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
CTD PMID:21354279 PMID:22542552 PMID:25655587 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions ISO
EXP
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
CTD PMID:21354279 PMID:22542552 PMID:25655587 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Met met proto-oncogene affects binding ISO piperine binds to MET protein CTD PMID:28341137 NCBI chr 6:17,463,349...17,573,980
Ensembl chr 6:17,463,800...17,573,980
JBrowse link
G Mmp14 matrix metallopeptidase 14 (membrane-inserted) multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 protein] CTD PMID:21354279 NCBI chr14:54,431,598...54,442,456
Ensembl chr14:54,431,612...54,445,364
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression ISO piperine results in decreased expression of MMP2 protein CTD PMID:15531295 NCBI chr 8:92,827,290...92,853,421
Ensembl chr 8:92,827,291...92,853,420
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]
piperine results in decreased expression of MMP9 protein
CTD PMID:15531295 PMID:21354279 NCBI chr 2:164,940,326...164,955,850
Ensembl chr 2:164,940,780...164,955,850
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein] CTD PMID:23707768 NCBI chr12:4,247,362...4,477,206
Ensembl chr12:4,247,362...4,477,182
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 decreases localization ISO piperine results in decreased localization of NFKB1 protein CTD PMID:15531295 NCBI chr 3:135,584,655...135,691,969
Ensembl chr 3:135,584,655...135,691,547
JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha multiple interactions ISO
EXP
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
CTD PMID:21354279 PMID:22542552 NCBI chr12:55,489,409...55,492,647
Ensembl chr12:55,489,410...55,492,647
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases expression
increases activity
affects binding
ISO [piperine co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]
piperine results in increased expression of NR1I2 protein
piperine results in increased activity of NR1I2 protein
piperine binds to NR1I2 protein
CTD PMID:23707768 PMID:25455453 NCBI chr16:38,248,349...38,294,849
Ensembl chr16:38,248,323...38,294,824
JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and affects the localization of PRKCA protein] CTD PMID:21354279 NCBI chr11:107,933,387...108,343,888
Ensembl chr11:107,933,387...108,343,928
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP piperine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] CTD PMID:22542552 NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
JBrowse link
G Rel reticuloendotheliosis oncogene decreases localization ISO piperine results in decreased localization of REL protein CTD PMID:15531295 NCBI chr11:23,736,847...23,770,969
Ensembl chr11:23,736,847...23,770,970
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions
decreases localization
ISO
EXP
piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of RELA protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and affects the localization of RELA protein]
piperine results in decreased localization of RELA protein
CTD PMID:15531295 PMID:21354279 PMID:22542552 NCBI chr19:5,637,442...5,648,134
Ensembl chr19:5,637,483...5,648,130
JBrowse link
G Slc9a3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 multiple interactions ISO [piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of SLC9A3 protein] CTD PMID:12806184 NCBI chr13:74,086,255...74,169,442
Ensembl chr13:74,121,457...74,169,442
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT3 protein] CTD PMID:25655587 NCBI chr11:100,886,806...100,939,594
Ensembl chr11:100,885,098...100,939,540
JBrowse link
G Stat5a signal transducer and activator of transcription 5A multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein] CTD PMID:25655587 NCBI chr11:100,859,351...100,885,169
Ensembl chr11:100,859,351...100,885,169
JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions EXP piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:25655587 NCBI chr11:100,780,731...100,859,004
Ensembl chr11:100,780,731...100,850,724
JBrowse link
G Tac1 tachykinin 1 decreases expression ISO piperine results in decreased expression of TAC1 protein CTD PMID:6205719 NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834
JBrowse link
G Tgfbr1 transforming growth factor, beta receptor I affects binding ISO piperine binds to TGFBR1 protein CTD PMID:28341137 NCBI chr 4:47,353,222...47,414,926
Ensembl chr 4:47,353,222...47,414,931
JBrowse link
G Tnf tumor necrosis factor decreases expression
decreases secretion
ISO piperine results in decreased expression of TNF mRNA
piperine results in decreased secretion of TNF protein
CTD PMID:15531295 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link
G Trp53 transformation related protein 53 multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of TP53 protein CTD PMID:30935902 NCBI chr11:69,580,348...69,591,873
Ensembl chr11:69,580,359...69,591,873
JBrowse link
G Ugdh UDP-glucose dehydrogenase decreases expression ISO piperine results in decreased expression of UGDH mRNA CTD PMID:16292757 NCBI chr 5:65,413,207...65,435,842
Ensembl chr 5:65,413,221...65,435,949
JBrowse link
G Utrn utrophin increases expression ISO piperine results in increased expression of UTRN mRNA CTD PMID:22028826 NCBI chr10:12,382,187...12,869,888
Ensembl chr10:12,382,188...12,869,365
JBrowse link
quinaprilat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc15a1 solute carrier family 15 (oligopeptide transporter), member 1 multiple interactions ISO quinaprilat inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr14:121,459,621...121,505,254
Ensembl chr14:121,459,621...121,505,252
JBrowse link
G Slc15a2 solute carrier family 15 (H+/peptide transporter), member 2 multiple interactions ISO quinaprilat inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr16:36,750,161...36,785,158
Ensembl chr16:36,750,177...36,784,962
JBrowse link
SCH772984 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle, aorta multiple interactions EXP SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:31706003 NCBI chr19:34,240,336...34,255,585
Ensembl chr19:34,241,090...34,255,590
JBrowse link
G Adm adrenomedullin decreases secretion
multiple interactions
ISO SCH772984 results in decreased secretion of ADM protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein]
CTD PMID:28087833 NCBI chr 7:110,627,657...110,629,820
Ensembl chr 7:110,627,661...110,629,820
JBrowse link
G App amyloid beta (A4) precursor protein multiple interactions ISO SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr16:84,952,666...85,175,255
Ensembl chr16:84,949,685...85,173,766
JBrowse link
G Ccl2 chemokine (C-C motif) ligand 2 multiple interactions ISO SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] CTD PMID:28087833 NCBI chr11:82,035,577...82,037,452
Ensembl chr11:82,035,571...82,037,453
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of and results in increased expression of CREB1 protein]; SCH772984 results in decreased phosphorylation of and results in decreased expression of CREB1 protein CTD PMID:28087833 NCBI chr 1:64,532,794...64,604,548
Ensembl chr 1:64,532,645...64,604,548
JBrowse link
G Cxcl1 chemokine (C-X-C motif) ligand 1 multiple interactions ISO SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein] CTD PMID:28087833 NCBI chr 5:90,891,245...90,893,121
Ensembl chr 5:90,891,241...90,893,115
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 mRNA]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 protein] CTD PMID:31585129 NCBI chr 7:140,763,819...140,774,990
Ensembl chr 7:140,763,739...140,774,987
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases secretion
ISO SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]
SCH772984 results in increased secretion of FGF2 protein
CTD PMID:28087833 NCBI chr 3:37,348,477...37,410,106
Ensembl chr 3:37,348,346...37,410,108
JBrowse link
G Fos FBJ osteosarcoma oncogene multiple interactions ISO [SCH772984 co-treated with bilobalide] inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; SCH772984 inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]] CTD PMID:28087833 PMID:32319158 NCBI chr12:85,473,890...85,477,274
Ensembl chr12:85,473,890...85,477,273
JBrowse link
G Gpr4 G protein-coupled receptor 4 multiple interactions ISO SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein] CTD PMID:33161135 NCBI chr 7:19,212,538...19,224,176
Ensembl chr 7:19,212,538...19,224,174
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions ISO SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr19:4,285,999...4,306,222
Ensembl chr19:4,286,001...4,306,222
JBrowse link
G Hspa1a heat shock protein 1A multiple interactions ISO SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of HSPA1A protein] CTD PMID:28087833 NCBI chr17:34,969,359...34,972,156
Ensembl chr17:34,969,190...34,972,156
JBrowse link
G Il6 interleukin 6 multiple interactions ISO SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of IL6 protein] CTD PMID:28087833 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
G Jun jun proto-oncogene multiple interactions ISO SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of JUN protein] CTD PMID:28087833 NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
JBrowse link
G Map2k1 mitogen-activated protein kinase kinase 1 increases phosphorylation ISO SCH772984 results in increased phosphorylation of MAP2K1 protein CTD PMID:28087833 NCBI chr 9:64,185,769...64,253,605
Ensembl chr 9:64,185,770...64,253,631
JBrowse link
G Map2k2 mitogen-activated protein kinase kinase 2 increases phosphorylation ISO SCH772984 results in increased phosphorylation of MAP2K2 protein CTD PMID:28087833 NCBI chr10:81,105,913...81,124,697
Ensembl chr10:81,105,915...81,133,975
JBrowse link
G Mapk1 mitogen-activated protein kinase 1 decreases expression
multiple interactions
increases phosphorylation
decreases activity
ISO SCH772984 results in decreased expression of MAPK1 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein]
SCH772984 results in increased phosphorylation of MAPK1 protein
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SCH772984 results in decreased activity of MAPK1 protein
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453
JBrowse link
G Mapk3 mitogen-activated protein kinase 3 increases phosphorylation
decreases activity
decreases expression
multiple interactions
ISO SCH772984 results in increased phosphorylation of MAPK3 protein
SCH772984 results in decreased activity of MAPK3 protein
SCH772984 results in decreased expression of MAPK3 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein]
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 decreases expression
multiple interactions
ISO SCH772984 results in decreased expression of MAPK8 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK8 protein]
CTD PMID:28087833 NCBI chr14:33,377,898...33,447,353
Ensembl chr14:33,377,898...33,447,158
JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions ISO SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of NFE2L2 protein] CTD PMID:28087833 NCBI chr 2:75,675,513...75,704,663
Ensembl chr 2:75,675,513...75,704,641
JBrowse link
G Sp1 trans-acting transcription factor 1 multiple interactions ISO SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of and results in increased phosphorylation of SP1 protein]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of SP1 mRNA] CTD PMID:31585129 NCBI chr15:102,406,316...102,436,404
Ensembl chr15:102,406,143...102,436,404
JBrowse link
G Spi1 spleen focus forming virus (SFFV) proviral integration oncogene multiple interactions ISO SCH772984 inhibits the reaction [saikosaponin D results in increased expression of SPI1 protein] CTD PMID:32822868 NCBI chr 2:91,082,374...91,115,759
Ensembl chr 2:91,082,390...91,115,756
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr 7:25,687,002...25,705,077
Ensembl chr 7:25,687,002...25,705,077
JBrowse link
G Vim vimentin multiple interactions EXP SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr 2:13,574,311...13,582,826
Ensembl chr 2:13,573,927...13,582,826
JBrowse link
spirapril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ren1 renin 1 structural increases expression
multiple interactions
ISO spirapril results in increased expression of REN mRNA; spirapril results in increased expression of REN protein
spirapril promotes the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein]
CTD PMID:1764812 PMID:9300315 NCBI chr 1:133,350,674...133,360,320
Ensembl chr 1:133,350,510...133,360,325
JBrowse link
G Slc15a1 solute carrier family 15 (oligopeptide transporter), member 1 multiple interactions ISO spirapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr14:121,459,621...121,505,254
Ensembl chr14:121,459,621...121,505,252
JBrowse link
G Slc15a2 solute carrier family 15 (H+/peptide transporter), member 2 multiple interactions ISO spirapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr16:36,750,161...36,785,158
Ensembl chr16:36,750,177...36,784,962
JBrowse link
trandolapril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 decreases activity ISO trandolapril results in decreased activity of ACE protein CTD PMID:27428043 NCBI chr11:105,967,948...105,989,964
Ensembl chr11:105,967,945...105,989,964
JBrowse link
G Ace2 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 multiple interactions EXP trandolapril promotes the reaction [REN2 protein results in increased expression of ACE2 protein] CTD PMID:27428043 NCBI chr  X:164,139,342...164,188,418
Ensembl chr  X:164,139,332...164,188,420
JBrowse link
G Ache acetylcholinesterase multiple interactions ISO trandolapril inhibits the reaction [3-nitropropionic acid results in increased activity of ACHE protein] CTD PMID:25445565 NCBI chr 5:137,288,247...137,294,466
Ensembl chr 5:137,287,519...137,294,466
JBrowse link
G Adrb1 adrenergic receptor, beta 1 increases expression ISO trandolapril results in increased expression of ADRB1 protein CTD PMID:7586371 NCBI chr19:56,722,117...56,725,150
Ensembl chr19:56,722,199...56,733,113
JBrowse link
G Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) multiple interactions
decreases expression
ISO
EXP
trandolapril inhibits the reaction [Isoproterenol results in increased expression of AGT protein]
trandolapril results in decreased expression of AGT protein modified form
trandolapril inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]
CTD PMID:1534315 PMID:27428043 NCBI chr 8:124,556,587...124,569,706
Ensembl chr 8:124,556,534...124,569,706
JBrowse link
G Cat catalase multiple interactions ISO trandolapril inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein] CTD PMID:25445565 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Cyba cytochrome b-245, alpha polypeptide multiple interactions
decreases expression
ISO [trandolapril co-treated with eplerenone] results in decreased expression of CYBA mRNA
trandolapril results in decreased expression of CYBA mRNA
CTD PMID:17324946 NCBI chr 8:122,424,771...122,432,940
Ensembl chr 8:122,424,776...122,432,930
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [trandolapril co-treated with eplerenone] results in decreased expression of FN1 protein CTD PMID:17324946 NCBI chr 1:71,585,473...71,653,280
Ensembl chr 1:71,585,520...71,653,200
JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions
decreases expression
ISO [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 mRNA; [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 protein
trandolapril results in decreased expression of NCF1 mRNA; trandolapril results in decreased expression of NCF1 protein
CTD PMID:17324946 NCBI chr 5:134,220,053...134,229,628
Ensembl chr 5:134,220,053...134,229,625
JBrowse link
G Ren1 renin 1 structural multiple interactions
increases expression
ISO [Bumetanide co-treated with trandolapril] results in increased expression of REN protein
trandolapril results in increased expression of REN protein
CTD PMID:16635047 PMID:27428043 NCBI chr 1:133,350,674...133,360,320
Ensembl chr 1:133,350,510...133,360,325
JBrowse link
G Ren2 renin 2 tandem duplication of Ren1 multiple interactions EXP trandolapril inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]; trandolapril inhibits the reaction [REN2 protein results in increased transport of 8-epi-prostaglandin F2alpha]; trandolapril promotes the reaction [REN2 protein results in increased abundance of angiotensin I (1-7)]; trandolapril promotes the reaction [REN2 protein results in increased expression of ACE2 protein]; trandolapril promotes the reaction [REN2 protein results in increased transport of Nitrogen Oxides] CTD PMID:27428043
G Slc15a1 solute carrier family 15 (oligopeptide transporter), member 1 multiple interactions ISO trandolapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr14:121,459,621...121,505,254
Ensembl chr14:121,459,621...121,505,252
JBrowse link
G Slc15a2 solute carrier family 15 (H+/peptide transporter), member 2 multiple interactions ISO trandolapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr16:36,750,161...36,785,158
Ensembl chr16:36,750,177...36,784,962
JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial increases expression ISO trandolapril results in increased expression of SOD2 protein CTD PMID:17324946 NCBI chr17:13,007,839...13,018,119
Ensembl chr17:13,006,846...13,040,063
JBrowse link
ximelagatran term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G F2 coagulation factor II decreases cleavage
multiple interactions
ISO ximelagatran results in decreased cleavage of F2 protein
ximelagatran binds to and results in decreased activity of F2 protein
CTD PMID:15155122 PMID:16084352 PMID:16194202 PMID:17314111 NCBI chr 2:91,612,397...91,636,457
Ensembl chr 2:91,625,320...91,636,414
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 21747
    chemical entity 21745
      atom 21732
        nonmetal atom 21628
          nitrogen atom 19404
            nitrogen molecular entity 19404
              organonitrogen compound 19129
                carboxamide 17809
                  tertiary carboxamide 185
                    (2R)-1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-2-pyrrolidinecarboxylic acid 0
                    (2R,3R,3aS,9bS)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-1-[cyclohexyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                    (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                    (2S,3S,3aR,9bR)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridine-2-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (4-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)[3-(3-hydroxy-3-methylbutyl)phenyl]methanone 0
                    (E)-dimethomorph + 11
                    (E)-flumorph + 0
                    (Z)-dimethomorph + 11
                    (Z)-flumorph + 0
                    1-(4-\{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl\}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone + 0
                    1-[4-(1-oxoprop-2-enyl)-1-piperazinyl]-2-propen-1-one 0
                    1-methyl-1-[1-oxo-1-(10H-phenothiazin-10-yl)propan-2-yl]pyrrolidinium + 0
                    1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester 0
                    2,2-dichloro-1-[5-(furan-2-yl)-2,2-dimethyl-1,3-oxazolidin-3-yl]ethanone + 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(ethanesulfonyl)amino]-5-fluoro-4-[4-methyl-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl]benzene-1-carbothioamide + 0
                    2-\{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy\}-N-(2-fluorophenyl)-N-methylpropanamide + 0
                    2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester 0
                    2-chloro-N-(2,6-dimethylphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide + 0
                    3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                    4-(dichloroacetyl)piperazine-1-carbaldehyde 0
                    4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 0
                    AZD1979 oxetane hydrolysis product 0
                    AZD7545 0
                    Adenocarpine 0
                    Allidochlor 0
                    Astrophylline 0
                    Casimiroedine 0
                    Dichlormid 0
                    Ethyl 3-(N-butylacetamido)propionate 0
                    GSK1016790A 0
                    GSK2656157 4
                    HMMF 0
                    LSM-14399 0
                    LSM-17487 0
                    LSM-17508 0
                    LSM-17532 0
                    LSM-17538 0
                    LSM-17628 0
                    LSM-17680 0
                    LSM-17740 0
                    LSM-25340 0
                    LSM-25384 0
                    LSM-25403 0
                    LSM-25515 0
                    LSM-25525 0
                    LSM-25537 0
                    LSM-25565 0
                    LSM-25598 0
                    LSM-9991 0
                    MK-8353 0
                    ML-210 0
                    ML162 0
                    N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                    N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                    N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                    N-(p-octylbenzoyl)-piperidin-4-ol 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(Z)-11-methyldodec-2-enoyl]piperidine 0
                    N-[(Z)-dodec-2-enoyl]morpholine 0
                    N-[(Z)-dodec-2-enoyl]piperidine 0
                    N-[(Z)-dodec-2-enoyl]pyrrolidine 0
                    N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                    N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                    N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide 0
                    N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide 0
                    N-isovalerylsarcosine 0
                    N1,N5,N10-Tricaffeoyl spermidine 0
                    OSMI-1 0
                    PF-07321332 0
                    PHA-533533 0
                    PHA-665752 12
                    R-29148 0
                    RSL3 0
                    SCH772984 24
                    SIS3 free base 0
                    acalabrutinib 2
                    althiomycin 0
                    butachlor 6
                    camostat 29
                    carfentanil 5
                    celacinnine 0
                    crotamiton 1
                    cyproflanilide 0
                    dalfopristin 0
                    delgocitinib 0
                    diloxanide furoate 0
                    erastin 30
                    ibrutinib 23
                    ivosidenib 0
                    lofentanyl 0
                    mefenacet 3
                    methylprednisolone 21-suleptanic acid ester 0
                    narlaprevir 0
                    nigerazine A 0
                    nigerazine B 0
                    nigragillin 0
                    onalespib 0
                    orthosulfamuron 0
                    piperine 63
                    pipobroman 0
                    pristinamycin IIA + 0
                    promysalin 0
                    pyrimorph 0
                    quinapril 0
                    quinaprilat 2
                    somocystinamide A 0
                    spirapril 3
                    spiraprilat + 3
                    trandolapril 14
                    trandolaprilat + 0
                    tyclopyrazoflor 0
                    ximelagatran 1
                    ximelagatran (hydroxylamine form) 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 21747
    subatomic particle 21732
      composite particle 21732
        hadron 21732
          baryon 21732
            nucleon 21732
              atomic nucleus 21732
                atom 21732
                  main group element atom 21649
                    p-block element atom 21649
                      carbon group element atom 21461
                        carbon atom 21363
                          organic molecular entity 21363
                            organic group 19925
                              organic divalent group 19912
                                organodiyl group 19912
                                  carbonyl group 19897
                                    carbonyl compound 19897
                                      carboxylic acid 19228
                                        carboacyl group 18033
                                          univalent carboacyl group 18033
                                            carbamoyl group 17809
                                              carboxamide 17809
                                                tertiary carboxamide 185
                                                  (2R)-1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-2-pyrrolidinecarboxylic acid 0
                                                  (2R,3R,3aS,9bS)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-1-[cyclohexyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                                                  (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                                                  (2S,3S,3aR,9bR)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridine-2-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (4-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)[3-(3-hydroxy-3-methylbutyl)phenyl]methanone 0
                                                  (E)-dimethomorph + 11
                                                  (E)-flumorph + 0
                                                  (Z)-dimethomorph + 11
                                                  (Z)-flumorph + 0
                                                  1-(4-\{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl\}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone + 0
                                                  1-[4-(1-oxoprop-2-enyl)-1-piperazinyl]-2-propen-1-one 0
                                                  1-methyl-1-[1-oxo-1-(10H-phenothiazin-10-yl)propan-2-yl]pyrrolidinium + 0
                                                  1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester 0
                                                  2,2-dichloro-1-[5-(furan-2-yl)-2,2-dimethyl-1,3-oxazolidin-3-yl]ethanone + 0
                                                  2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(ethanesulfonyl)amino]-5-fluoro-4-[4-methyl-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl]benzene-1-carbothioamide + 0
                                                  2-\{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy\}-N-(2-fluorophenyl)-N-methylpropanamide + 0
                                                  2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester 0
                                                  2-chloro-N-(2,6-dimethylphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide + 0
                                                  3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                                                  4-(dichloroacetyl)piperazine-1-carbaldehyde 0
                                                  4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 0
                                                  AZD1979 oxetane hydrolysis product 0
                                                  AZD7545 0
                                                  Adenocarpine 0
                                                  Allidochlor 0
                                                  Astrophylline 0
                                                  Casimiroedine 0
                                                  Dichlormid 0
                                                  Ethyl 3-(N-butylacetamido)propionate 0
                                                  GSK1016790A 0
                                                  GSK2656157 4
                                                  HMMF 0
                                                  LSM-14399 0
                                                  LSM-17487 0
                                                  LSM-17508 0
                                                  LSM-17532 0
                                                  LSM-17538 0
                                                  LSM-17628 0
                                                  LSM-17680 0
                                                  LSM-17740 0
                                                  LSM-25340 0
                                                  LSM-25384 0
                                                  LSM-25403 0
                                                  LSM-25515 0
                                                  LSM-25525 0
                                                  LSM-25537 0
                                                  LSM-25565 0
                                                  LSM-25598 0
                                                  LSM-9991 0
                                                  MK-8353 0
                                                  ML-210 0
                                                  ML162 0
                                                  N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                                                  N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                                                  N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                                                  N-(p-octylbenzoyl)-piperidin-4-ol 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(Z)-11-methyldodec-2-enoyl]piperidine 0
                                                  N-[(Z)-dodec-2-enoyl]morpholine 0
                                                  N-[(Z)-dodec-2-enoyl]piperidine 0
                                                  N-[(Z)-dodec-2-enoyl]pyrrolidine 0
                                                  N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                                                  N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                                                  N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide 0
                                                  N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide 0
                                                  N-isovalerylsarcosine 0
                                                  N1,N5,N10-Tricaffeoyl spermidine 0
                                                  OSMI-1 0
                                                  PF-07321332 0
                                                  PHA-533533 0
                                                  PHA-665752 12
                                                  R-29148 0
                                                  RSL3 0
                                                  SCH772984 24
                                                  SIS3 free base 0
                                                  acalabrutinib 2
                                                  althiomycin 0
                                                  butachlor 6
                                                  camostat 29
                                                  carfentanil 5
                                                  celacinnine 0
                                                  crotamiton 1
                                                  cyproflanilide 0
                                                  dalfopristin 0
                                                  delgocitinib 0
                                                  diloxanide furoate 0
                                                  erastin 30
                                                  ibrutinib 23
                                                  ivosidenib 0
                                                  lofentanyl 0
                                                  mefenacet 3
                                                  methylprednisolone 21-suleptanic acid ester 0
                                                  narlaprevir 0
                                                  nigerazine A 0
                                                  nigerazine B 0
                                                  nigragillin 0
                                                  onalespib 0
                                                  orthosulfamuron 0
                                                  piperine 63
                                                  pipobroman 0
                                                  pristinamycin IIA + 0
                                                  promysalin 0
                                                  pyrimorph 0
                                                  quinapril 0
                                                  quinaprilat 2
                                                  somocystinamide A 0
                                                  spirapril 3
                                                  spiraprilat + 3
                                                  trandolapril 14
                                                  trandolaprilat + 0
                                                  tyclopyrazoflor 0
                                                  ximelagatran 1
                                                  ximelagatran (hydroxylamine form) 0
paths to the root